India is entering a distinctly different phase of healthcare innovation - across Biotech, Pharma, and MedTech.
What’s changing isn’t just the number of startups, but the nature of what’s being built.
In Biotech, founders are moving from services to platforms - biological measurement, cell & gene engineering, and biomanufacturing. These are areas where IP, data, and regulatory depth compound over time and shape long-term outcomes.
In Pharma, AI is steadily re-wiring the value chain - from drug discovery and experiment design to clinical trial operations, medical writing, compliance, and real-world analytics. The impact is structural, even if it shows up quietly at first.
In MedTech, devices are converging with software - spanning implants, diagnostics, wearables, and remote monitoring - where hardware, data, clinical validation, and regulation have to scale together.
Across all three pillars, the pattern is consistent:
- Long gestation cycles and significant regulatory friction
- High capex with limited early commercial signals
But the potential to build durable, globally relevant businesses
These are not sectors where conviction is built from early revenue curves.
They are shaped in labs, regulatory strategy, manufacturing processes, and clinical pathways - often years before traditional venture metrics become visible.
What’s notable is that this same pattern now extends well beyond healthcare.
We see it across Climate & Energy, Mobility, Robotics, Space, Advanced Manufacturing, and Frontier AI - domains where early technical and design choices matter far more than short-term momentum.
This is why deeptech investing needs a different operating model.
At Chiratae Ventures, this perspective has been informed by working closely with companies such as SigTuple (AI-enabled diagnostics), Forus Health (ophthalmic screening devices), Axio Biosolutions (advanced wound-care biomaterials), and Zumutor Biologics (immuno-oncology therapeutics).
These experiences reinforced a simple insight:
Founders in long-gestation, technically complex sectors benefit most from patient, informed, and high-conviction partnerships.
At Chiratae Ventures, this thesis led us to build Sonic – DeepTech Edition - a platform designed for founders building in long-gestation, technically complex sectors across healthcare and frontier engineering.
⏱️ 48-hour evaluation cycle
💸 Up to $2M from Seed to Series A
🤝 Access to domain experts and ecosystem partners
If you are building in Pharma, Biotech and Medtech, I’d love to speak with you. Apply via link: : https://lnkd.in/gbhc-C-u
With Saharsh Sharma and the entire team at Chiratae Ventures
#Pharma #Deeptech #Medtech #Biotech #Innovation #Startup
